A review concludes that combination therapy with metformin and GLP-1 receptor agonists provides the most comprehensive treatment for obese PCOS patients by addressing both metabolic and reproductive aspects of the condition.
Metformin + GLP-1RARecommended combination therapy for PCOS patients with insulin resistance and obesity, addressing both metabolic dysfunction and reproductive aspects of the condition
What the researchers found
The review identifies GLP-1 receptor agonists as effective treatments that improve both metabolic and reproductive outcomes in PCOS. The key recommendation is that PCOS patients with insulin resistance and obesity would benefit most from combination therapy with metformin and GLP-1 receptor agonists, which provides comprehensive treatment for both the reproductive and metabolic aspects of the condition.
Other effective interventions include myoinositol (for ovarian function), resveratrol (metabolic and reproductive benefits), and bariatric surgery for severe obesity. Lifestyle modifications remain the first-line approach.
Why it matters
PCOS is the most common endocrine disorder in women of reproductive age, affecting 6-12% of women. Obesity significantly worsens PCOS symptoms and complicates fertility. GLP-1 receptor agonists, already widely used for diabetes and obesity, represent an emerging treatment option that uniquely addresses multiple aspects of PCOS — weight, insulin resistance, hormonal balance, and reproductive function.
How the study worked
Non-systematic review of English-language papers published between 2010 and 2024, searched in MEDLINE. The review covers pathophysiology differences between obese and non-obese PCOS, clinical presentation, and therapeutic strategies including lifestyle, pharmacological, and surgical approaches.
What this study cannot tell us
This is a non-systematic review, meaning the literature search was not comprehensive or reproducible. No meta-analysis was performed. The review covers studies from 2010-2024, and some newer evidence (e.g., tirzepatide for PCOS) may not be included. The specific GLP-1 receptor agonists studied in PCOS are not detailed. Evidence quality for GLP-1RAs in PCOS is still limited compared to their evidence in diabetes and obesity.
How to read the evidence
This is a non-systematic narrative review without meta-analysis. While it provides a useful clinical overview, the evidence synthesis methodology is less rigorous than a systematic review. The strength of evidence for GLP-1RAs in PCOS specifically is still building compared to their well-established efficacy in diabetes and obesity.
When this study was published
Published in 2025, this review is timely given the explosive growth of GLP-1 receptor agonist use and increasing interest in their applications for women's health conditions like PCOS.
The bigger picture
This review reflects the expanding therapeutic applications of GLP-1 receptor agonist peptide drugs beyond diabetes and obesity into women's reproductive health. The recognition that these peptide therapies can address the metabolic root causes of PCOS — not just symptoms — represents a paradigm shift toward treating the underlying pathophysiology of this common condition.
Questions still open
- Which specific GLP-1 receptor agonist (semaglutide, liraglutide, tirzepatide) is most effective for PCOS?
- Does GLP-1 receptor agonist treatment in PCOS improve fertility outcomes and pregnancy rates?
- Should GLP-1 receptor agonists be continued during attempts at conception, or stopped before pregnancy?
Common questions
Can GLP-1 drugs like semaglutide help with PCOS?
Is it safe to use GLP-1 medications while trying to get pregnant?
Read the original research
Obesity as a Part of Polycysric Ovary Syndrome (PCOS)-A Review of Pathophysiology and Comprehensive Therapeutic Strategies.
Journal of clinical medicine, 14(16)
Citation
Bila, Jovan; Dotlic, Jelena; Andjic, Mladen; Ivanovic, Katarina; Micic, Jelena; Tulic, Lidija; Pupovac, Miljan; Stojnic, Jelena; Vukovic, Ivana; Ivanovic, Stefan. (2025). Obesity as a Part of Polycysric Ovary Syndrome (PCOS)-A Review of Pathophysiology and Comprehensive Therapeutic Strategies.. Journal of clinical medicine, 14(16). https://doi.org/10.3390/jcm14165642